Research & News

argenx will gain early access to Chai’s AI platform to support de novo antibody discovery against therapeutic targets

Announcing our $400M fundraise

Novartis will gain access to Chai Discovery’s AI design models and platform to support therapeutic antibody discovery across multiple targets.

This represents the first instance of TuneLab bringing outside models onto the service, Lilly's Aliza Apple said.

This agreement — Chai’s second with Lilly — enables biotechs in early biologics discovery to evaluate Chai’s miniprotein design suite.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies.

Pfizer scientists will leverage Chai Discovery’s AI platform - including Chai-3, its most advanced model - alongside custom software.

Announcing our $130M fundraise

With Chai-2, we’re moving de novo antibody design past binding and closer than ever to real therapeutics.

Announcing our $70M fundraise

We’re excited to release Chai-2, a new series of models that achieve double digit hit rates in de novo antibody design.

We’re excited to release Chai-1, a new multi-modal foundation model for molecular structure prediction that performs at the state-of-the-art across a variety of tasks relevant to drug discovery.

Announcing our first fundraise